Induced Pluripotent Stem Cell (iPS) Program

IPS technology has revolutionized modern medicine as offers the possibility of being a tool by which current drug discovery and safety testing programs might be accelerated.

  1. Induced Pluripotent Stem Cell (iPS) Program

Induced Pluripotent Stem Cell (iPS) Program

The usability of human induced pluripotent stemcell (iPS) technology has revolutionized modern medicine. Aside from its potential use in the cell therapy sector as human material to produce treatments for a variety of disorders with unmet clinical needs, iPS technology also offers the possibility of being  a tool by which current drug discovery and safety testing programs might be accelerated and made more specific, in particular for orphan drug development.  

In orphan drug development, many pre-clinical testing platforms that are based on animal species prove to be of limited predictive value due to biochemical and pathophysiological variations from humans. iPS-derived somatic cells offer an alternative platform for pre-clinical developmental studies for novel therapeutics in rare disease. The cells also afford a predictive platform at the pre-clinical to clinical interface in novel therapeutics in rare hereditary diseases. Furthermore, the ability of patient-specific iPS-derived cells to model genetic and epigenetic variations of a broad spectrum population may also speed up phase 1/2 development of new treatment in rare diseases.  

In this manner, Centogene has developed international scientific networks for the collection of well-defined patient derived skin biopsies which are  the basis for iPS material. This material has the potential to lower the time, costs, and risks associated with the development of drugs for any hereditary diseases. It is within this context that Centogene is collaborating with global pharmaceutical partners. 



  • offer a platform for pre-clinical developmental studies for novel therapeutics in rare disease
  • afford a predictive platform at the pre-clinical to clinical interface in novel therapeutics in rare diseases
  • able to model genetic and epigenetic variations of a broad spectrum population and may potentially speed up phase 1/2 development of new treatment in rare diseases.